Zimbabwe Selected for Global Rollout of Lenacapavir, Breakthrough Twice-Yearly HIV Prevention Drug
Key Insights
Zimbabwe has been chosen as one of only ten countries worldwide to introduce lenacapavir, a groundbreaking HIV (search) prevention drug developed by Gilead Sciences that requires only twice-yearly injections.
Clinical trials demonstrated that more than 99 percent of participants taking lenacapavir remained HIV (search)-negative, marking a significant advancement in HIV prevention technology.
The rollout will prioritize pregnant and breastfeeding women to protect the next generation, with Zimbabwe's 1.3 million HIV (search)-positive population potentially benefiting from this breakthrough treatment.
Zimbabwe has been selected as one of only ten countries globally to roll out lenacapavir, a revolutionary HIV (search) prevention drug that could transform the fight against the epidemic. The announcement was made by the United States Embassy in Harare, which described the development as a major step toward ending new HIV infections in the country.
Developed by U.S.-based Gilead Sciences in partnership with the Global Fund (search), lenacapavir represents a significant breakthrough as the first twice-yearly injectable medicine designed to prevent HIV (search) infection. This dosing schedule marks a dramatic improvement over existing prevention methods, potentially enhancing patient adherence and reducing the burden of daily medication regimens.
Clinical Trial Results Demonstrate Exceptional Efficacy
Large-scale clinical trials have demonstrated remarkable effectiveness for lenacapavir, with more than 99 percent of people taking the drug remaining HIV (search)-negative. This exceptional efficacy rate positions lenacapavir as one of the most promising HIV prevention tools developed to date.
Health experts note that the medicine could significantly reduce new infections, particularly among vulnerable populations. The U.S. Embassy emphasized that Zimbabwe's rollout will focus on pregnant and breastfeeding women, ensuring protection for both mothers and the next generation.
Addressing Zimbabwe's HIV Burden
Zimbabwe remains one of the countries hardest hit by HIV (search), with nearly 1.3 million people living with the virus according to UNAIDS (search) data. However, infection rates have steadily declined over the past two decades thanks to increased access to antiretroviral therapy and prevention programmes.
The introduction of lenacapavir is expected to strengthen the country's health systems while making prevention more affordable and accessible. Public health experts believe this development could mark a turning point in the fight against the epidemic, particularly in sub-Saharan Africa where new infections remain high.
Global Impact and Future Outlook
"Zimbabwe's selection for the introduction of lenacapavir marks a historic milestone in our collective fight against HIV (search)," the U.S. Embassy stated. "This is American leadership at its best: driving innovation and building a world where children, mothers, and communities can thrive."
The Embassy characterized the development as "more than medicine," describing it as "a pathway to a safer, stronger, and healthier future for Zimbabwe." With the introduction of lenacapavir, Zimbabwe could accelerate progress toward achieving the global target of ending AIDS (search) as a public health threat by 2030.